Is MOLN or ALLO more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Molecular Partners N/A -66.62% -54.85% Allogene Therapeutics N/A -56.45% -40.36%

Does the media prefer MOLN or ALLO?

In the previous week, Allogene Therapeutics had 2 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Allogene Therapeutics and 1 mentions for Molecular Partners. Allogene Therapeutics' average media sentiment score of 0.53 beat Molecular Partners' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLMD or MOLN more profitable?

Molecular Partners' return on equity of -66.62% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -71.22% -64.46% Molecular Partners N/A -66.62% -54.85%

Does the media favor RLMD or MOLN?

In the previous week, Relmada Therapeutics had 2 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for Molecular Partners. Relmada Therapeutics' average media sentiment score of 0.65 beat Molecular Partners' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RGNX or MOLN?

In the previous week, REGENXBIO had 9 more articles in the media than Molecular Partners. MarketBeat recorded 10 mentions for REGENXBIO and 1 mentions for Molecular Partners. REGENXBIO's average media sentiment score of 0.21 beat Molecular Partners' score of 0.00 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MOLN or PRME?

In the previous week, Molecular Partners and Molecular Partners both had 1 articles in the media. Prime Medicine's average media sentiment score of 1.63 beat Molecular Partners' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor CTMX or MOLN?

In the previous week, CytomX Therapeutics had 2 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Molecular Partners. CytomX Therapeutics' average media sentiment score of 0.60 beat Molecular Partners' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Molecular Partners (MOLN) Competitors

$4.00 +0.00 (+0.08%)

As of 11:57 AM Eastern

Compare

MOLN vs. ALLO, RLMD, RGNX, PRME, and CTMX

Should you buy Molecular Partners stock or one of its competitors? MarketBeat compares Molecular Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Molecular Partners include Allogene Therapeutics (ALLO), Relmada Therapeutics (RLMD), REGENXBIO (RGNX), Prime Medicine (PRME), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry.

How does Molecular Partners compare to Allogene Therapeutics?

Molecular Partners (NASDAQ:MOLN) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Molecular Partners has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.61	-$74.41M	-$1.94	N/A
Allogene Therapeutics	$20K	31,322.36	-$190.89M	-$0.77	N/A

Molecular Partners has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Molecular Partners presently has a consensus target price of $8.38, suggesting a potential upside of 109.22%. Allogene Therapeutics has a consensus target price of $8.52, suggesting a potential upside of 369.54%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Allogene Therapeutics' return on equity of -56.45% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Allogene Therapeutics	N/A	-56.45%	-40.36%

In the previous week, Allogene Therapeutics had 2 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Allogene Therapeutics and 1 mentions for Molecular Partners. Allogene Therapeutics' average media sentiment score of 0.53 beat Molecular Partners' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Allogene Therapeutics beats Molecular Partners on 12 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 130.99%. Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 109.22%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Relmada Therapeutics has higher earnings, but lower revenue than Molecular Partners. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Molecular Partners	$5.65M	28.61	-$74.41M	-$1.94	N/A

Relmada Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Molecular Partners' return on equity of -66.62% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Molecular Partners	N/A	-66.62%	-54.85%

In the previous week, Relmada Therapeutics had 2 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for Molecular Partners. Relmada Therapeutics' average media sentiment score of 0.65 beat Molecular Partners' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Relmada Therapeutics beats Molecular Partners on 10 of the 15 factors compared between the two stocks.

How does Molecular Partners compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

REGENXBIO has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Molecular Partners has lower revenue, but higher earnings than REGENXBIO. Molecular Partners is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.14	-$193.88M	-$5.60	N/A
Molecular Partners	$5.65M	28.61	-$74.41M	-$1.94	N/A

In the previous week, REGENXBIO had 9 more articles in the media than Molecular Partners. MarketBeat recorded 10 mentions for REGENXBIO and 1 mentions for Molecular Partners. REGENXBIO's average media sentiment score of 0.21 beat Molecular Partners' score of 0.00 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Molecular Partners has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Molecular Partners' return on equity of -66.62% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
Molecular Partners	N/A	-66.62%	-54.85%

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

REGENXBIO currently has a consensus price target of $23.82, indicating a potential upside of 130.35%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 109.22%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts plainly believe REGENXBIO is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

REGENXBIO beats Molecular Partners on 9 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to Prime Medicine?

Molecular Partners (NASDAQ:MOLN) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Molecular Partners has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.26, suggesting that its share price is 126% more volatile than the broader market.

Molecular Partners currently has a consensus target price of $8.38, indicating a potential upside of 109.22%. Prime Medicine has a consensus target price of $7.53, indicating a potential upside of 142.55%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Molecular Partners and Molecular Partners both had 1 articles in the media. Prime Medicine's average media sentiment score of 1.63 beat Molecular Partners' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Molecular Partners has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Molecular Partners' return on equity of -66.62% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Molecular Partners has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.61	-$74.41M	-$1.94	N/A
Prime Medicine	$4.63M	121.13	-$201.14M	-$1.23	N/A

Summary

Prime Medicine beats Molecular Partners on 10 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CytomX Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

CytomX Therapeutics has higher revenue and earnings than Molecular Partners. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.60	-$17.37M	-$0.41	N/A
Molecular Partners	$5.65M	28.61	-$74.41M	-$1.94	N/A

In the previous week, CytomX Therapeutics had 2 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Molecular Partners. CytomX Therapeutics' average media sentiment score of 0.60 beat Molecular Partners' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Molecular Partners has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Molecular Partners	N/A	-66.62%	-54.85%

CytomX Therapeutics presently has a consensus target price of $12.10, indicating a potential upside of 255.36%. Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 109.22%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe CytomX Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

CytomX Therapeutics beats Molecular Partners on 13 of the 17 factors compared between the two stocks.

Get Molecular Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOLN vs. The Competition

Export

Metric	Molecular Partners	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$161.48M	$3.64B	$6.80B	$12.40B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-2.06	20.61	27.08	24.12
Price / Sales	28.61	304.69	516.47	92.58
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.67	8.04	10.63	6.23
Net Income	-$74.41M	$23.81M	$3.60B	$331.53M
7 Day Performance	0.83%	-1.31%	-1.08%	-1.30%
1 Month Performance	4.79%	2.48%	1.28%	-1.40%
1 Year Performance	5.51%	44.40%	24.71%	18.15%

Molecular Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOLN Molecular Partners	2.3801 of 5 stars	$4.00 +0.1%	$8.38 +109.2%	+10.3%	$161.48M	$5.65M	N/A	180
ALLO Allogene Therapeutics	1.9232 of 5 stars	$1.90 +2.7%	$8.52 +348.5%	+41.6%	$655.79M	$20K	N/A	310
RLMD Relmada Therapeutics	2.3587 of 5 stars	$6.21 flat	$12.00 +93.2%	+766.6%	$651.37M	N/A	N/A	10
RGNX REGENXBIO	3.6278 of 5 stars	$12.27 -0.2%	$23.82 +94.1%	+26.5%	$634.33M	$87.82M	N/A	370
PRME Prime Medicine	3.3234 of 5 stars	$3.48 +0.3%	$7.53 +116.4%	N/A	$628.56M	$4.63M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOLN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Molecular Partners (MOLN) Competitors

MOLN vs. ALLO, RLMD, RGNX, PRME, and CTMX

How does Molecular Partners compare to Allogene Therapeutics?

Summary

How does Molecular Partners compare to Relmada Therapeutics?

Summary

How does Molecular Partners compare to REGENXBIO?

Summary

How does Molecular Partners compare to Prime Medicine?

Summary

How does Molecular Partners compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Molecular Partners (MOLN) Competitors

MOLN vs. ALLO, RLMD, RGNX, PRME, and CTMX

How does Molecular Partners compare to Allogene Therapeutics?

Do institutionals & insiders hold more shares of MOLN or ALLO?

Which has better valuation and earnings, MOLN or ALLO?

Which has more volatility & risk, MOLN or ALLO?

Do analysts recommend MOLN or ALLO?

Is MOLN or ALLO more profitable?

Does the media prefer MOLN or ALLO?

Summary

How does Molecular Partners compare to Relmada Therapeutics?

Do analysts prefer RLMD or MOLN?

Which has stronger valuation & earnings, RLMD or MOLN?

Which has more volatility & risk, RLMD or MOLN?

Is RLMD or MOLN more profitable?

Does the media favor RLMD or MOLN?

Do institutionals and insiders have more ownership in RLMD or MOLN?

Summary

How does Molecular Partners compare to REGENXBIO?

Which has more risk and volatility, RGNX or MOLN?

Which has better earnings and valuation, RGNX or MOLN?

Does the media favor RGNX or MOLN?

Is RGNX or MOLN more profitable?

Do institutionals & insiders have more ownership in RGNX or MOLN?

Do analysts rate RGNX or MOLN?

Summary

How does Molecular Partners compare to Prime Medicine?

Which has more risk & volatility, MOLN or PRME?

Do analysts rate MOLN or PRME?

Do insiders & institutionals believe in MOLN or PRME?

Does the media prefer MOLN or PRME?

Is MOLN or PRME more profitable?

Which has stronger valuation and earnings, MOLN or PRME?

Summary

How does Molecular Partners compare to CytomX Therapeutics?

Do institutionals and insiders have more ownership in CTMX or MOLN?

Which has more risk & volatility, CTMX or MOLN?

Which has stronger earnings and valuation, CTMX or MOLN?

Does the media favor CTMX or MOLN?

Is CTMX or MOLN more profitable?

Do analysts rate CTMX or MOLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools